Immunotherapy for Cancer in India
How checkpoint inhibitors and other immunotherapies work, which cancers they treat, costs in India, and what to expect.
Immunotherapy works by helping your own immune system recognise and attack cancer cells. Unlike chemotherapy which directly kills cells, immunotherapy removes the brakes that cancer puts on your immune response. The most common type used today are checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4).
In India, immunotherapy has transformed outcomes for lung cancer, melanoma, kidney cancer, bladder cancer, and several other types. Pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq) are the most prescribed agents. Costs remain high at INR 80,000-1,50,000 per infusion, though biosimilars are entering the market.
Not everyone benefits from immunotherapy. PD-L1 expression testing, MSI status, and tumour mutational burden help predict who will respond. About 20-40% of eligible patients see significant responses, but when it works, the responses can be remarkably durable, lasting years in some cases.
How Immunotherapy Works
Mechanism: Cancer cells hide from your immune system by expressing PD-L1, which tells T-cells to stand down. Checkpoint inhibitors block this signal, allowing T-cells to attack the tumour again.
During treatment: IV infusion every 2-3 weeks, taking 30-60 minutes. Given as daycare. No pre-medication nausea prophylaxis needed (unlike chemo). Can be combined with chemotherapy for stronger effect.
Response pattern: Unlike chemo, responses can take 6-12 weeks to appear. Some tumours initially appear larger on scans (pseudoprogression) before shrinking. Patience and experienced oncologist interpretation are key.
Duration: Typically continued for up to 2 years if responding. Some patients achieve complete remission and stop treatment. Maintenance schedules vary by drug and cancer type.
Common Immunotherapy Regimens and Costs
| Regimen | Drugs | Duration | Approx. Cost |
|---|---|---|---|
| Pembrolizumab (lung, cervical, melanoma) | Pembrolizumab 200mg IV q3w | Until progression or 2 years | INR 80,000-1,20,000 per dose |
| Nivolumab (kidney, liver, melanoma) | Nivolumab 240mg IV q2w | Until progression or 2 years | INR 70,000-1,00,000 per dose |
| Atezolizumab (bladder, lung) | Atezolizumab 1200mg IV q3w | Until progression | INR 1,00,000-1,50,000 per dose |
| Durvalumab (lung, bladder) | Durvalumab 10mg/kg IV q2w | Up to 12 months | INR 80,000-1,20,000 per dose |
| Ipilimumab + Nivolumab (melanoma, kidney) | Combination anti-CTLA4 + anti-PD1 | 4 combination cycles then nivolumab alone | INR 3,00,000+ per combination cycle |
Side Effects and Management
| Side Effect | How Common | How We Manage It |
|---|---|---|
| Immune-related colitis | 1-5% | Monitor for diarrhea >4x/day; hold drug; prednisone 1-2mg/kg; infliximab if steroid-resistant |
| Immune hepatitis | 1-3% | Monitor LFTs every 2 cycles; hold drug if AST/ALT >3x upper limit; steroids |
| Immune pneumonitis | 1-3% | Watch for cough, dyspnea; chest imaging if suspected; steroids and drug discontinuation |
| Thyroid dysfunction | 5-10% | TSH monitoring every 6-8 weeks; levothyroxine if hypothyroid; usually manageable |
| Skin rash | 10-20% | Topical steroids for mild; systemic steroids for severe; dermatology referral if widespread |
| Fatigue | 20-30% | Generally milder than chemo fatigue; rule out thyroid/adrenal causes; activity as tolerated |
Cancers Treated with Immunotherapy
Immunotherapy Treatment by City
Questions About Immunotherapy?
Our specialists can explain whether immunotherapy is right for your cancer type and guide you through the process.
Book a Free Consultation